Transatlantique Private Wealth LLC Takes $512,000 Position in Kenvue Inc. $KVUE

Transatlantique Private Wealth LLC purchased a new stake in shares of Kenvue Inc. (NYSE:KVUE) during the fourth quarter, HoldingsChannel.com reports. The institutional investor purchased 29,688 shares of the company’s stock, valued at approximately $512,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Kennon Green & Company LLC lifted its holdings in shares of Kenvue by 0.8% during the fourth quarter. Kennon Green & Company LLC now owns 223,736 shares of the company’s stock valued at $3,859,000 after purchasing an additional 1,787 shares in the last quarter. CIBC Asset Management Inc lifted its holdings in shares of Kenvue by 54.6% during the fourth quarter. CIBC Asset Management Inc now owns 491,896 shares of the company’s stock valued at $8,485,000 after purchasing an additional 173,725 shares in the last quarter. Bruce G. Allen Investments LLC lifted its holdings in shares of Kenvue by 29.8% during the fourth quarter. Bruce G. Allen Investments LLC now owns 6,579 shares of the company’s stock valued at $113,000 after purchasing an additional 1,509 shares in the last quarter. Westpac Banking Corp lifted its holdings in shares of Kenvue by 21.1% during the fourth quarter. Westpac Banking Corp now owns 30,638 shares of the company’s stock valued at $529,000 after purchasing an additional 5,336 shares in the last quarter. Finally, New Mexico Educational Retirement Board lifted its holdings in shares of Kenvue by 1.6% during the fourth quarter. New Mexico Educational Retirement Board now owns 88,181 shares of the company’s stock valued at $1,521,000 after purchasing an additional 1,400 shares in the last quarter. 97.64% of the stock is owned by institutional investors.

Kenvue Stock Up 0.2%

Kenvue stock opened at $16.87 on Friday. The stock has a market cap of $32.38 billion, a PE ratio of 19.84, a price-to-earnings-growth ratio of 1.28 and a beta of 0.54. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.70 and a current ratio of 0.98. Kenvue Inc. has a one year low of $14.02 and a one year high of $22.87. The stock has a fifty day moving average of $17.37 and a 200 day moving average of $17.47.

Kenvue (NYSE:KVUE) last posted its quarterly earnings data on Thursday, May 7th. The company reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of $0.27 by $0.05. The company had revenue of $3.91 billion during the quarter, compared to analysts’ expectations of $3.84 billion. Kenvue had a return on equity of 20.81% and a net margin of 10.61%.Kenvue’s revenue for the quarter was up 4.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.24 earnings per share. As a group, sell-side analysts predict that Kenvue Inc. will post 1.16 EPS for the current year.

Kenvue Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, May 27th. Shareholders of record on Wednesday, May 13th were given a $0.2075 dividend. The ex-dividend date was Wednesday, May 13th. This represents a $0.83 dividend on an annualized basis and a yield of 4.9%. Kenvue’s dividend payout ratio is presently 97.65%.

Wall Street Analyst Weigh In

KVUE has been the topic of a number of research analyst reports. Zacks Research raised Kenvue from a “hold” rating to a “strong-buy” rating in a report on Friday, May 8th. Argus raised Kenvue to a “hold” rating in a report on Friday, March 6th. UBS Group lowered their price target on Kenvue from $19.00 to $18.00 and set a “neutral” rating on the stock in a report on Tuesday, April 7th. Weiss Ratings downgraded Kenvue from a “hold (c)” rating to a “hold (c-)” rating in a report on Friday, May 29th. Finally, Canaccord Genuity Group upped their price objective on Kenvue from $17.00 to $18.00 and gave the company a “hold” rating in a research report on Wednesday, February 18th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and twelve have issued a Hold rating to the company’s stock. According to MarketBeat, Kenvue has a consensus rating of “Hold” and an average target price of $19.33.

Insider Buying and Selling

In other Kenvue news, General Counsel Matthew Orlando sold 38,491 shares of the company’s stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $17.66, for a total value of $679,751.06. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.59% of the stock is currently owned by insiders.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.